Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study

医学 卡培他滨 全直肠系膜切除术 结直肠癌 奥沙利铂 临床终点 新辅助治疗 放化疗 肿瘤科 临床研究阶段 化疗 癌症 内科学 外科 随机对照试验 乳腺癌
作者
Gong Chen,Ying Jin,Wen‐Long Guan,Rongxin Zhang,Weiwei Xiao,Peiqiang Cai,Min Liu,Junzhong Lin,Fulong Wang,Cong Li,Tingting Quan,Shaoyan Xi,Huizhong Zhang,Zhizhong Pan,Rui Wang,Rui‐Hua Xu
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:8 (5): 422-431 被引量:51
标识
DOI:10.1016/s2468-1253(22)00439-3
摘要

Summary

Background

The current standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by radical surgery, but this approach can lead to multiple complications. We aimed to investigate the clinical activity and safety of neoadjuvant therapy with sintilimab, a single-agent PD-1 antibody, in patients with mismatch-repair deficient locally advanced rectal cancer.

Methods

This open-label, single-arm, phase 2 study was done at the Sun Yat-sen University Cancer Center, Guangzhou, China. Patients aged 18–75 years with mismatch-repair deficient or microsatellite instability-high locally advanced rectal cancer were enrolled and received neoadjuvant sintilimab monotherapy (200 mg by intravenous infusion) every 21 days. After an initial four cycles of treatment, patients and clinicians could choose one of the following options: total mesorectal excision surgery, followed by four cycles of adjuvant sintilimab with or without CapeOX chemotherapy (capecitabine 1000 mg/m2, orally administered twice daily on days 1–14; oxaliplatin 130 mg/m2, intravenously administered on day 1 every 3 weeks), determined by clinicians; or another four cycles of sintilimab followed by radical surgery or observation (only for patients with a clinical complete response; also known as the watch and wait strategy). The primary endpoint was the complete response rate, which included both a pathological complete response after surgery and a clinical complete response after completion of sintilimab treatment. Clinical response was evaluated by digital rectal examination, MRI, and endoscopy. Response was assessed in all patients who received treatment at least until the first tumour response assessment, after the first two cycles of sintilimab. Safety was analysed in all patients who received at least one dose of treatment. This trial is closed to enrolment and is registered with ClinicalTrials.gov (NCT04304209).

Findings

Between Oct 19, 2019, and June 18, 2022, 17 patients were enrolled and received at least one dose of sintilimab. The median age was 50 years (IQR 35–59) and 11 (65%) of 17 patients were male. One patient was excluded from efficacy analyses because they were lost to follow-up after the first sintilimab cycle. Of the remaining 16 patients, six underwent surgery, of whom three had a pathological complete response. Nine other patients had a clinical complete response and chose the watch and wait strategy. One patient had a serious adverse event and discontinued treatment; this patient did not have a complete clinical response and refused to undergo surgery. A complete response was thus noted for 12 (75%; 95% CI 47–92) of 16 patients. One of the three patients who underwent surgery but did not have a pathological complete response showed an increase in tumour volume after the initial four cycles of sintilimab (at which point they underwent surgery); this patient was deemed to have primary resistance to immune checkpoint inhibitors. After a median follow-up of 17·2 (IQR 8·2–28·5) months, all patients were alive and none had disease recurrence. Only one (6%) patient had a grade 3–4 adverse event, which was deemed a serious adverse event (grade 3 encephalitis).

Interpretation

The preliminary results of this study suggest that anti-PD-1 monotherapy is effective and tolerable for patients with mismatch-repair deficient locally advanced rectal cancer and could potentially spare some patients from radical surgery. Longer treatment courses might be needed to achieve maximum effects in some patients. Longer follow-up is also needed to observe the duration of response.

Funding

The National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, Science and Technology Program of Guangzhou, and Innovent Biologics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冷傲半烟发布了新的文献求助10
1秒前
2秒前
Cecilia完成签到,获得积分10
3秒前
liu完成签到,获得积分10
4秒前
Cecilia发布了新的文献求助10
6秒前
JXC完成签到,获得积分10
6秒前
黄飚完成签到,获得积分10
7秒前
8秒前
小胖完成签到,获得积分10
8秒前
唐瑾瑜完成签到,获得积分10
11秒前
哈哈哈哈哈哈完成签到,获得积分10
11秒前
12秒前
13秒前
13秒前
krislang完成签到,获得积分10
14秒前
rundstedt完成签到,获得积分10
15秒前
菠萝谷波发布了新的文献求助10
16秒前
燕子完成签到,获得积分10
17秒前
喆喆发布了新的文献求助20
19秒前
iNk举报王洋求助涉嫌违规
19秒前
20秒前
隐形曼青应助菠萝谷波采纳,获得10
23秒前
24秒前
27秒前
28秒前
rundstedt发布了新的文献求助10
30秒前
30秒前
了一李应助13686682012采纳,获得10
31秒前
InfoNinja应助jack采纳,获得50
31秒前
笑点低的幼旋完成签到,获得积分10
32秒前
甜蜜绿蓉发布了新的文献求助10
35秒前
小刘完成签到,获得积分10
35秒前
111112完成签到,获得积分10
36秒前
充电宝应助喆喆采纳,获得10
37秒前
lwg完成签到,获得积分10
37秒前
37秒前
38秒前
大闲鱼铭一完成签到 ,获得积分10
40秒前
费费发布了新的文献求助10
41秒前
41秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
The Data Economy: Tools and Applications 1000
Diamonds: Properties, Synthesis and Applications 800
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufen 700
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3096463
求助须知:如何正确求助?哪些是违规求助? 2748430
关于积分的说明 7599646
捐赠科研通 2400115
什么是DOI,文献DOI怎么找? 1273385
科研通“疑难数据库(出版商)”最低求助积分说明 615728
版权声明 598973